Rezolute, Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
For fiscal year ended June 30, 2026, Rezolute reported net loss of $77.6M (vs. $74.4M prior year) on R&D expenses of $53.8M (vs. $61.5M prior year). Cash and investments declined to $107.8M from $167.9M year-over-year. The Phase 3 upLIFT study in tumor HI shows strong interim data: 7 of 8 enrolled patients met the primary endpoint (6 achieved complete IV glucose discontinuation). However, the Phase 3 sunRIZE study in congenital HI failed its primary endpoint; FDA review is ongoing and the company notes a failed randomized trial could force abandonment of that indication.
Why this rating
Strong tumor HI data partially offsets congenital HI failure. Cash burn (~$60M annually) sustainable for ~1.8 years at current runway. Regulatory pathway uncertainty is material but upLIFT progress supports near-term valuation.
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.